KROS 株価推移チャート
KROS 収入
Keros Therapeutics Inc
$11.99
2.91%
$0.33
終値： May 13, 16:00:00 GMT-4
$11.99
0%
$0
プレマーケット： May 14, 07:34:35 GMT-4
戻る
Keros Therapeutics Inc (KROS) 収入
最新の利益結果: Q4 '25
報告済み: 2026-03-04
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
KROSの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Keros Therapeutics Inc KROSの前四半期の収益はどうでしたか？
Keros Therapeutics Incの収益見積もりはいくらですか？
Keros Therapeutics Incの収益品質スコアはどれくらいですか？
Keros Therapeutics Incはいつ収益を報告しますか？
Keros Therapeutics Incの予想収益はいくらですか？
Keros Therapeutics Incは収益予想を上回りましたか？
主要データ
前終値
$11.65
始値
$11.58
当日レンジ
$11.41 - $12.01
52週レンジ
$10.41 - $22.55
取引高
343.5K
平均取引高
387.1K
配当利回り
--
1株当たり利益(TTM)
1.82
時価総額
$236.4M
KROSとは何ですか？
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
